STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma

Cancer Letters

Volumn 325, Issue 1, 2012, Pages 80-88

  Tu, Bing ^a   Du, Lin ^a   Fan, Qi Ming ^a   Tang, Ze ^a   Tang, Ting Ting ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Interleukin 6; Mesenchymal stem cells; Osteosarcoma; STAT3

Indexed keywords

CYCLIN D; CYCLINE; INTERLEUKIN 6; LUCIFERASE; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NEUTRALIZING ANTIBODY; PROTEIN BCL XL; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CELL LABELING; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG METASTASIS; MALE; MESENCHYMAL STEM CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; CYCLIN D; DISEASE PROGRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-6; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEOSARCOMA; PROLIFERATING CELL NUCLEAR ANTIGEN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

MUS; MUS MUSCULUS;

EID: 84865295971     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.06.006     Document Type: Article

References (48)

1. Longhi A., Errani C., De Paolis M., Mercuri M., Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006, 32:423-436.
2. Tan M.L., Choong P.F., Dass C.R. Osteosarcoma: conventional treatment vs. gene therapy. Cancer Biol. Ther. 2009, 8:106-117.
3. Gorlick R., Khanna C. Osteosarcoma. J. Bone Miner. Res. 2010, 25:683-691.
4. Meyers P.A., Gorlick R. Osteosarcoma. Pediatr. Clin. North Am. 1997, 44:973-989.
5. Kuhn N.Z., Tuan R.S. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. J. Cell Physiol. 2010, 222:268-277.
6. Bian Z.Y., Li G., Gan Y.K., Hao Y.Q., Xu W.T., Tang T.T. Increased number of mesenchymal stem cell-like cells in peripheral blood of patients with bone sarcomas. Arch. Med. Res. 2009, 40:163-168.
7. Xu W.T., Bian Z.Y., Fan Q.M., Li G., Tang T.T. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 2009, 281:32-41.
8. Siclari V.A., Qin L. Targeting the osteosarcoma cancer stem cell. J. Orthop. Surg. Res. 2010, 5:78.
9. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
10. Bergfeld S.A., DeClerck Y.A. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010, 29:249-261.
11. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
12. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 2008, 14:109-119.
13. Jourdan M., Reme T., Goldschmidt H., Fiol G., Pantesco V., De Vos J., Rossi J.F., Hose D., Klein B. Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. Br. J. Haematol. 2009, 145:45-58.
14. Heikkila K., Ebrahim S., Lawlor D.A. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer 2008, 44:937-945.
15. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
16. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
17. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334(Pt 2):297-314.
18. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21:11-19.
19. Barre B., Vigneron A., Perkins N., Roninson I.B., Gamelin E., Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol. Med. 2007, 13:4-11.
20. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., Baumann H., Wetzler M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002, 99:252-257.
21. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19:6613-6626.
22. Deng J., Grande F., Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drug Targets. 2007, 7:91-107.
23. Ryu K., Choy E., Yang C., Susa M., Hornicek F.J., Mankin H., Duan Z. Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J. Orthop. Res. 2010, 28:971-978.
24. Bian Z.Y., Fan Q.M., Li G., Xu W.T., Tang T.T. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci. 2010, 101:2554-2560.
25. Tang T., Lu H., Dai K. Osteogenesis of freeze-dried cancellous bone allograft loaded with autologous marrow-derived mesenchymal cells. Mater. Sci. Eng. C 2002, 20:57-61.
26. Luu H.H., Kang Q., Park J.K., Si W., Luo Q., Jiang W., Yin H., Montag A.G., Simon M.A., Peabody T.D., Haydon R.C., Rinker-Schaeffer C.W., He T.C. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metastasis 2005, 22:319-329.
27. Hazlehurst L.A., Landowski T.H., Dalton W.S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003, 22:7396-7402.
28. Meyers P.A., Schwartz C.L., Krailo M., Kleinerman E.S., Betcher D., Bernstein M.L., Conrad E., Ferguson W., Gebhardt M., Goorin A.M., Harris M.B., Healey J., Huvos A., Link M., Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R., Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 2005, 23:2004-2011.
29. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
30. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 2008, 14:2519-2526.
31. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
32. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., Pearce B.D., Landry J., Glover S., McDaniel J.S., Nemeroff C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatr. 2001, 158:1252-1257.
33. Knupfer H., Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 2007, 102:129-135.
34. Xin H., Zhang C., Herrmann A., Du Y., Figlin R., Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009, 69:2506-2513.
35. Chauhan D., Kharbanda S., Ogata A., Urashima M., Teoh G., Robertson M., Kufe D.W., Anderson K.C. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997, 89:227-234.
36. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., Nam S., Eweis I., Diaz N., Sullivan D., Yoder S., Enkemann S., Eschrich S., Lee J.H., Beam C.A., Cheng J., Minton S., Muro-Cacho C.A., Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006, 12:11-19.
37. Hardin J., MacLeod S., Grigorieva I., Chang R., Barlogie B., Xiao H., Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994, 84:3063-3070.
38. Chung T.D., Yu J.J., Kong T.A., Spiotto M.T., Lin J.M. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000, 42:1-7.
39. Lin L., Liu A., Peng Z., Lin H.J., Li P.K., Li C., Lin J. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011.
40. Iwamaru A., Szymanski S., Iwado E., Aoki H., Yokoyama T., Fokt I., Hess K., Conrad C., Madden T., Sawaya R., Kondo S., Priebe W., Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007, 26:2435-2444.
41. He G., Yu G.Y., Temkin V., Ogata H., Kuntzen C., Sakurai T., Sieghart W., Peck-Radosavljevic M., Leffert H.L., Karin M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010, 17:286-297.
42. Onimoe G.I., Liu A., Lin L., Wei C.C., Schwartz E.B., Bhasin D., Li C., Fuchs J.R., Li P.K., Houghton P., Termuhlen A., Gross T., Lin J. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest. New Drugs 2012, 30:916-926.
43. Chen C.L., Loy A., Cen L., Chan C., Hsieh F.C., Cheng G., Wu B., Qualman S.J., Kunisada K., Yamauchi-Takihara K., Lin J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007, 7:111.
44. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin. Cancer Res. 2007, 13:1362-1366.
45. Xie T.X., Huang F.J., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., Xie K., Sawaya R., Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006, 66:3188-3196.
46. Zhang P., Yang Y., Zweidler-McKay P.A., Hughes D.P. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin. Cancer Res. 2008, 14:2962-2969.
47. Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 2004, 90:2312-2316.
48. Kinoshita T., Ito H., Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999, 85:2526-2531.